MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from issuance of
common stock, net of...
$54,724K
Proceeds from the
exercise of stock options
$149K
Sales and maturities
of short-term and...
$67,965K
Net cash provided by
financing activities
$54,873K
Net cash used in
investing activities
$3,582K
Canceled cashflow
$64,383K
Net increase
(decrease) in cash and cash...
$16,563K
Canceled cashflow
$41,892K
Stock-based compensation
expense
$5,485K
Accounts payable
$2,807K
Operating lease
liabilities
$47K
Other assets
-$37K
Purchase of short-term
and long-term...
$64,383K
Net cash used in
operating activities
-$41,892K
Canceled cashflow
$8,376K
Net loss
-$43,320K
Accrued expenses
-$3,828K
Prepaid expenses and
other current assets
$2,561K
Amortization/accretion of bond
discounts/premiums
-$559K
Back
Back
Cash Flow
ArriVent BioPharma, Inc. (AVBP)
ArriVent BioPharma, Inc. (AVBP)
source: myfinsight.com